What are the major opportunities in the Familial Amyloid Polyneuropathy market? What are the strategies for the Familial Amyloid Polyneuropathy market?

For detailed insights on the major opportunities and strategies in the Familial Amyloid Polyneuropathy market, Read More

How does the Familial Amyloid Polyneuropathy market relate to the overall economy and other similar markets?

For detailed insights on Familial Amyloid Polyneuropathy's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Familial Amyloid Polyneuropathy market growth? SWOT analysis of the Familial Amyloid Polyneuropathy market.

For detailed insights on the key dynamics influencing the Familial Amyloid Polyneuropathy market growth and SWOT analysis of the Familial Amyloid Polyneuropathy industry, Read More

Global Familial Amyloid Polyneuropathy Market Report 2025

Item added to cart!

Published : December 2025

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Familial Amyloid Polyneuropathy Global Market Report 2025

Name: Familial Amyloid Polyneuropathy Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Treatment (Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment), By Diagnosis (Genetic Testing, Biopsy, Imaging, Other Diagnosis), By Patient Age Group (Pediatric, Adult, Geriatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales), By End-User (Hospitals, Specialty Clinics, Research Institutes, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Familial Amyloid Polyneuropathy Market?

Familial amyloid polyneuropathy (FAP) is a rare genetic disorder caused by mutations in the transthyretin (TTR) gene, resulting in the accumulation of amyloid proteins in peripheral nerves and key organs. This progressive disease mainly targets the nervous system, leading to sensory, motor, and autonomic dysfunction. Early diagnosis and effective management aim to slow disease progression, alleviate symptoms, and enhance the patient’s quality of life.

The main types of familial amyloid polyneuropathy treatment are medication, gene therapy, supportive care, pain management, and symptomatic treatment. Medication helps manage familial amyloid polyneuropathy by slowing disease progression, relieving symptoms, and improving patients' quality of life. It is diagnosed by various methods, including genetic testing, biopsy, imaging, and others, for different patient age groups, including pediatric, adult, and geriatric. It is distributed through several distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, specialty pharmacies, and direct sales, and is used by several end-users, including hospitals, specialty clinics, research institutes, and others.

Familial Amyloid Polyneuropathy Market Size and growth rate 2025 to 2029: Graph

What Is The Familial Amyloid Polyneuropathy Market Size 2025 And Growth Rate?

The familial amyloid polyneuropathy market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the increasing prevalence of familial amyloid polyneuropathy, rising awareness and diagnosis rates due to improved genetic testing, growing adoption of novel therapeutic options and targeted treatments, increasing investment in research and development for amyloidosis therapies, and a rising geriatric population susceptible to amyloid-related neuropathies.

What Is The Familial Amyloid Polyneuropathy Market Growth Forecast?

The familial amyloid polyneuropathy market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing government initiatives and funding to support rare disease treatments, an increasing number of clinical trials evaluating innovative treatment candidates, rising patient advocacy and support groups driving demand for better therapies, growing accessibility to healthcare infrastructure in emerging markets, and increasing availability of advanced diagnostic tools. Major trends in the forecast period include advancements in genetic sequencing technologies, integration of personalized medicine, technology improvements in biomarker identification, advancements in drug delivery systems, and integration of digital health tools and telemedicine.

Book your 30 minutes free consultation with our research experts

How Is The Familial Amyloid Polyneuropathy Market Segmented?

The familial amyloid polyneuropathy market covered in this report is segmented –

1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment

2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis

3) By Patient Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales

5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran

2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy

3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling

4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants

5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment

What Is Driving The Familial Amyloid Polyneuropathy Market? The Rising Focus On Gene Therapy Is Fueling The Growth Of The Market Due To Its Ability To Target And Correct Defective Genes For Lasting Familial Amyloid Polyneuropathy Treatment

The rising focus on gene therapy is expected to propel the growth of the familial amyloid polyneuropathy market going forward. Gene therapy is a treatment method that modifies or replaces defective genes to address the underlying cause of diseases. Gene therapy is gaining momentum as it targets and fixes faulty genes, offering lasting or permanent cures rather than just symptom relief. Gene therapy for familial amyloid polyneuropathy focuses on correcting or silencing the defective transthyretin (TTR) gene to prevent harmful amyloid protein formation. This helps reduce amyloid deposits, slowing disease progression and preserving nerve function. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of the first quarter of 2023, there were 247 gene therapies in Phase II, this number rose by 5% to reach 260 by the end of the second quarter. Therefore, the rising focus on gene therapy is driving the growth of the familial amyloid polyneuropathy market.

Who Are The Major Players In The Global Familial Amyloid Polyneuropathy Market?

Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, YolTech Therapeutics.

What Are The Key Trends Of The Global Familial Amyloid Polyneuropathy Market? Advancements In RNAi Therapeutics Transform Familial Amyloid Polyneuropathy Treatment

Major companies operating in the familial amyloid polyneuropathy market are focused on developing advanced treatment solutions, such as RNA interference (RNAi) therapeutics, to slow disease progression and improve patient outcomes. RNA interference (RNAi) therapeutics are advanced treatments that silence disease-causing genes by targeting their messenger RNA (mRNA). This approach blocks the production of harmful proteins, addressing genetic diseases at their source. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, launched AMVUTTRA (vutrisiran), which received approval from the Food and Drug Administration (FDA) for treating cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is administered as four subcutaneous doses per year and designed to treat both ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). By reducing the production of transthyretin (TTR) protein, the root cause of the disease, it significantly lowers cardiovascular mortality, hospitalizations, and urgent heart failure visits, as demonstrated in the HELIOS-B Phase 3 clinical trial.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Familial Amyloid Polyneuropathy Market? Alnylam Pharmaceuticals Partnered With Medison Pharma To Expand Global Access To RNAi Therapies For Rare Diseases

In March 2023, Alnylam Pharmaceuticals, a US-based provider of RNAi therapeutics for treating hereditary transthyretin-mediated amyloidosis, partnered with Medison Pharma to expand access to innovative RNAi therapies worldwide. The partnership aims to accelerate and broaden global patient access to Alnylam’s RNAi therapeutics for rare and severe diseases by leveraging Medison Pharma’s unified commercialization platform across international regions. Medison Pharma is an Israel-based pharmaceutical company.

What Is The Regional Outlook For The Global Familial Amyloid Polyneuropathy Market?

North America was the largest region in the familial amyloid polyneuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the familial amyloid polyneuropathy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Familial Amyloid Polyneuropathy Market?

The familial amyloid polyneuropathy market consists of revenues earned by entities providing services such as disease monitoring, patient support and education, neurological assessment, and genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The familial amyloid polyneuropathy market also includes sales of transthyretin stabilizers, diagnostic kits, and monitoring equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Familial Amyloid Polyneuropathy Industry?

The familial amyloid polyneuropathy market research report is one of a series of new reports from The Business Research Company that provides familial amyloid polyneuropathy market statistics, including the familial amyloid polyneuropathy industry global market size, regional shares, competitors with the familial amyloid polyneuropathy market share, detailed familial amyloid polyneuropathy market segments, market trends, opportunities, and any further data you may need to thrive in the familial amyloid polyneuropathy industry. This familial amyloid polyneuropathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abhilash Pyata

Familial Amyloid Polyneuropathy Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.65 billion
Revenue Forecast In 2034	$2.25 billion
Growth Rate	CAGR of 8.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The familial amyloid polyneuropathy market covered in this report is segmented – 1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment 2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis 3) By Patient Age Group: Pediatric, Adult, Geriatric 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales 5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users Subsegments: 1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran 2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy 3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling 4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants 5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Prothena Corporation plc, Precision BioSciences Inc., Intellia Therapeutics Inc., Creative Biolabs, Stanford Health Care, Attralus Inc., Duke University Health System, YolTech Therapeutics.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Familial Amyloid Polyneuropathy Market Characteristics

3. Familial Amyloid Polyneuropathy Market Trends And Strategies

4. Familial Amyloid Polyneuropathy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Familial Amyloid Polyneuropathy Growth Analysis And Strategic Analysis Framework

5.1. Global Familial Amyloid Polyneuropathy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Familial Amyloid Polyneuropathy Market Growth Rate Analysis

5.4. Global Familial Amyloid Polyneuropathy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Familial Amyloid Polyneuropathy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Familial Amyloid Polyneuropathy Total Addressable Market (TAM)

6. Familial Amyloid Polyneuropathy Market Segmentation

6.1. Global Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Medication

Gene Therapy

Supportive Care

Pain Management

Symptomatic Treatment

6.2. Global Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Genetic Testing

Biopsy

Imaging

Other Diagnosis

6.3. Global Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pediatric

Adult

Geriatric

6.4. Global Familial Amyloid Polyneuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Specialty Pharmacies

Direct Sales

6.5. Global Familial Amyloid Polyneuropathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Research Institutes

Other End-Users

6.6. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Transthyretin (TTR) Stabilizers

Transthyretin (TTR) Gene Silencers

Tafamidis

Diflunisal

Patisiran

6.7. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy

RNA Interference (RNAi) Therapy

Antisense Oligonucleotides (ASO) Therapy

6.8. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Physical Therapy

Occupational Therapy

Nutritional Support

Psychological Counseling

6.9. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Pain Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Opioids

Antidepressants

Anticonvulsants

6.10. Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gastrointestinal Symptom Management

Cardiovascular Symptom Management

Autonomic Dysfunction Management

Orthostatic Hypotension Treatment

7. Familial Amyloid Polyneuropathy Market Regional And Country Analysis

7.1. Global Familial Amyloid Polyneuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Familial Amyloid Polyneuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Familial Amyloid Polyneuropathy Market

8.1. Asia-Pacific Familial Amyloid Polyneuropathy Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Familial Amyloid Polyneuropathy Market

9.1. China Familial Amyloid Polyneuropathy Market Overview

9.2. China Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Familial Amyloid Polyneuropathy Market

10.1. India Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Familial Amyloid Polyneuropathy Market

11.1. Japan Familial Amyloid Polyneuropathy Market Overview

11.2. Japan Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Familial Amyloid Polyneuropathy Market

12.1. Australia Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Familial Amyloid Polyneuropathy Market

13.1. Indonesia Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Familial Amyloid Polyneuropathy Market

14.1. South Korea Familial Amyloid Polyneuropathy Market Overview

14.2. South Korea Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Familial Amyloid Polyneuropathy Market

15.1. Western Europe Familial Amyloid Polyneuropathy Market Overview

15.2. Western Europe Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Familial Amyloid Polyneuropathy Market

16.1. UK Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Familial Amyloid Polyneuropathy Market

17.1. Germany Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Familial Amyloid Polyneuropathy Market

18.1. France Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Familial Amyloid Polyneuropathy Market

19.1. Italy Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Familial Amyloid Polyneuropathy Market

20.1. Spain Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Familial Amyloid Polyneuropathy Market

21.1. Eastern Europe Familial Amyloid Polyneuropathy Market Overview

21.2. Eastern Europe Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Familial Amyloid Polyneuropathy Market

22.1. Russia Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Familial Amyloid Polyneuropathy Market

23.1. North America Familial Amyloid Polyneuropathy Market Overview

23.2. North America Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Familial Amyloid Polyneuropathy Market

24.1. USA Familial Amyloid Polyneuropathy Market Overview

24.2. USA Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Familial Amyloid Polyneuropathy Market

25.1. Canada Familial Amyloid Polyneuropathy Market Overview

25.2. Canada Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Familial Amyloid Polyneuropathy Market

26.1. South America Familial Amyloid Polyneuropathy Market Overview

26.2. South America Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Familial Amyloid Polyneuropathy Market

27.1. Brazil Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Familial Amyloid Polyneuropathy Market

28.1. Middle East Familial Amyloid Polyneuropathy Market Overview

28.2. Middle East Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Familial Amyloid Polyneuropathy Market

29.1. Africa Familial Amyloid Polyneuropathy Market Overview

29.2. Africa Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Familial Amyloid Polyneuropathy Market Competitive Landscape And Company Profiles

30.1. Familial Amyloid Polyneuropathy Market Competitive Landscape

30.2. Familial Amyloid Polyneuropathy Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. NYU Langone Hospitals Overview, Products and Services, Strategy and Financial Analysis

31. Familial Amyloid Polyneuropathy Market Other Major And Innovative Companies

31.1. Alexion Pharmaceuticals Inc.

31.2. Alnylam Pharmaceuticals Inc.

31.3. Mount Sinai Medical Center

31.4. PTC Therapeutics Inc.

31.5. Ionis Pharmaceuticals Inc.

31.6. Mayo Foundation for Medical Education and Research

31.7. Arcturus Therapeutics Inc.

31.8. Prothena Corporation plc

31.9. Precision BioSciences Inc.

31.10. Intellia Therapeutics Inc.

31.11. Creative Biolabs

31.12. Stanford Health Care

31.13. Attralus Inc.

31.14. Duke University Health System

31.15. YolTech Therapeutics

32. Global Familial Amyloid Polyneuropathy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Familial Amyloid Polyneuropathy Market

34. Recent Developments In The Familial Amyloid Polyneuropathy Market

35. Familial Amyloid Polyneuropathy Market High Potential Countries, Segments and Strategies

35.1 Familial Amyloid Polyneuropathy Market In 2029 - Countries Offering Most New Opportunities

35.2 Familial Amyloid Polyneuropathy Market In 2029 - Segments Offering Most New Opportunities

35.3 Familial Amyloid Polyneuropathy Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Familial Amyloid Polyneuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Familial Amyloid Polyneuropathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Pain Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Familial Amyloid Polyneuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Global Familial Amyloid Polyneuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Asia-Pacific, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: China, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: India, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Japan, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Australia, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: Indonesia, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: South Korea, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: Western Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: UK, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Germany, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: France, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Italy, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Spain, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Eastern Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Russia, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: North America, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: USA, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Canada, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: South America, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Brazil, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Middle East, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: Africa, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 81: Pfizer Inc. Financial Performance

Table 82: AstraZeneca plc Financial Performance

Table 83: Novo Nordisk A/S Financial Performance

Table 84: Regeneron Pharmaceuticals Inc. Financial Performance

Table 85: NYU Langone Hospitals Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Familial Amyloid Polyneuropathy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Familial Amyloid Polyneuropathy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Pain Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Familial Amyloid Polyneuropathy Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Familial Amyloid Polyneuropathy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Global Familial Amyloid Polyneuropathy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Asia-Pacific, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: China, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: India, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Japan, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Australia, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: Indonesia, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: South Korea, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: Western Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: UK, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Germany, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: France, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Italy, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Spain, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Eastern Europe, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Russia, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: North America, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: USA, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Canada, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: South America, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Brazil, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Middle East, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Familial Amyloid Polyneuropathy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Familial Amyloid Polyneuropathy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: Africa, Familial Amyloid Polyneuropathy Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 81: Pfizer Inc. Financial Performance

Figure 82: AstraZeneca plc Financial Performance

Figure 83: Novo Nordisk A/S Financial Performance

Figure 84: Regeneron Pharmaceuticals Inc. Financial Performance

Figure 85: NYU Langone Hospitals Financial Performance

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Forecast 2025–2034: Trends Reshaping Demand, Investment, and Innovation

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Projected to Reach $47.74 Billion by 2029 at a CAGR of 30.7%

$8.21 Billion Forecast for Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market by 2029, Backed by Demand and Innovation

Fentanyl Market Forecast Reaching $22.03 Billion by 2029 at 6.5% CAGR

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Transthyretin Amyloidosis Treatment Global Market Report 2025 – By Type (Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)), By Drug (Tafamidis, Patisiran, I...

Diabetic Neuropathy Global Market Report 2025 – By Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Drug Class (Analgesics, Anti-Depressants, Anti-convulsant, Other Drug C...

Rare Neurological Disease Treatment Global Market Report 2025 – By Drug Type (Biologics, Small Molecules), By Therapy (Cognitive Behavioral Therapy, Interpersonal Psychotherapy, Cyberknife, Other Therapies), By Mode Of A...

Neurofibromatosis Treatment Global Market Report 2025 – By Type (Neurofibromatosis 1 (NF–, Neurofibromatosis 2 (NF, Schwannomatosis), By Treatment (Medications, Surgery, Radiation Therapy, Other Treatments), By End-Users...

Neurological Biomarkers Global Market Report 2025 – By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products), By Application (Alzheimer’s Disease, Parkinson’s Disea...

Progressive Ataxia And Weakness Disorders Global Market Report 2025 – By Type (Progressive Ataxia, Progressive Weakness Disorders), By Technology (Small Molecule, Monoclonal Antibody, Other Technology), By Distribution C...

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2025 – By Drug Class (Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes), By Tr...

Frequently Asked Questions

What is the definition of the Familial Amyloid Polyneuropathy market?

How will the Familial Amyloid Polyneuropathy market drivers and restraints affect the market dynamics? What forces will shape the Familial Amyloid Polyneuropathy industry going forward?

The Familial Amyloid Polyneuropathy market major growth driver - The Rising Focus On Gene Therapy Is Fueling The Growth Of The Market Due To Its Ability To Target And Correct Defective Genes For Lasting Familial Amyloid Polyneuropathy Treatment. For further insights on the Familial Amyloid Polyneuropathy market, request a sample here

What is the forecast market size or the forecast market value of the Familial Amyloid Polyneuropathy market?

The Familial Amyloid Polyneuropathy market size has grown strongly in recent years. The familial amyloid polyneuropathy market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.65 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the increasing prevalence of familial amyloid polyneuropathy, rising awareness and diagnosis rates due to improved genetic testing, growing adoption of novel therapeutic options and targeted treatments, increasing investment in research and development for amyloidosis therapies, and a rising geriatric population susceptible to amyloid-related neuropathies. The familial amyloid polyneuropathy market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing government initiatives and funding to support rare disease treatments, an increasing number of clinical trials evaluating innovative treatment candidates, rising patient advocacy and support groups driving demand for better therapies, growing accessibility to healthcare infrastructure in emerging markets, and increasing availability of advanced diagnostic tools. Major trends in the forecast period include advancements in genetic sequencing technologies, integration of personalized medicine, technology improvements in biomarker identification, advancements in drug delivery systems, and integration of digital health tools and telemedicine. For further insights on the Familial Amyloid Polyneuropathy market, request a sample here

How is the Familial Amyloid Polyneuropathy market segmented?

The familial amyloid polyneuropathy market covered in this report is segmented –
1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment
2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis
3) By Patient Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:
1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran
2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy
3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling
4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants
5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment For further insights on the Familial Amyloid Polyneuropathy market, request a sample here

Which region has the largest share of the Familial Amyloid Polyneuropathy market? What are the other regions covered in the report?

Who are the major players in the Familial Amyloid Polyneuropathy market?

What are the key trends in the Familial Amyloid Polyneuropathy market?

Major trends in the Familial Amyloid Polyneuropathy market include Advancements In RNAi Therapeutics Transform Familial Amyloid Polyneuropathy Treatment. For further insights on the Familial Amyloid Polyneuropathy market, request a sample here.